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INTRODUCTION
The national incidence of 28,635 cases of viral hepatitist during the
first four months of 1961 was the highest for any comparable period since
the disease became reportable in 1952.1 The attack rate was 16 per 100,000,
a figure more than double the 6.9 per 100,000 rate reported for the first
16 weeks in 1960.
The age distribution curves of infectious hepatitis showed a striking
shift toward the adult age groups in 1959 and 1960. In past years the
highest incidence was observed in the pediatric age group, i.e., persons
under 15 years of age.' Currently available statistics for the New England
and Middle Atlantic States indicate that more than 50 per cent of the
reported cases of hepatitis were adults over 20 years of age.1
The increasing incidence of infectious hepatitis, especially in adults,
has been a source of concern to physicians and public health officials. This
situation has created a renewed interest in gamma globulin, the only
available prophylactic agent against this disease. The increased demand
for immune serum globulin has highlighted the importance of defining its
virtues and limitations as well as resolving the current confusion in regard
to optimum dosage.
THE GAMMA GLOBULIN DILEMMA
An adequate evaluation of the efficacy of gamma globulin in the
prevention of infectious hepatitis requires precise information about i)
the susceptibility of the host, ii) the type of exposure to the virus, and
iii) the IH antibody content of the preparation used.
*Professor of Pediatrics, New York University, School of Medicine.
**Professor of Pediatrics, University of Southern California. Formerly Research
Assistant (Assistant Professor) in Section of Preventive Medicine, Yale University
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tThis includes both infectious hepatitis (IH) and serum hepatitis (SH). The num-
ber of SH cases, however, represents only a very small fraction of the total figure.
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Host Susceptibility. The susceptibility of the host cannot be measured
accurately. At the present time a serological test is not available for the
titration of infectious hepatitis neutralizing antibodies. In general chil-
dren are more susceptible than adults. Most adults have acquired their
immunity following an unrecognized anicteric infection contracted in
childhood.
The incidence of infectious hepatitis among children and adults fol-
lowing intimate household contacts was reported by Brooks et al.' and
Hsia et al.' As indicated in Table 1 the attack rate in children was 32
TABLE 1. INCIDENCE OF INFECTIOUS HEPATITIS IN CHILDREN AND
ADULTS FOLLOWING INTIMATE HOUSEHOLD CONTACT
Controls who did not receive gamma globulin
Study No. 1* Study No. 2** Combined totals
No. No. zwith No. No. with No. No. zith
Study groups exposed hepatitis exposed hepatitis exposed hepatitis
Children 15 18 (35%) 40 11 (27%) 91 29 (32%)
< 15 years
Adults 63 0 (0%) 55 2 (4%) 118 2 (1.7%)
> 15 years
* From, Brooks, Hsia and Gellis, New Engl. J. Med., 1953, 249, 58.
** From, Hsia, Lonsway and Gellis, New Engl. J. Med., 1954, 250, 417.
per cent; in 118 adults over 15 years it was only 1.7 per cent. The
adults in these studies were subjected to the same exposure which was
followed by an attack rate of 32 per cent in children. Consequently, the
resistance to infection was due most likely to immunity rather than
inadequate exposure. An inoculation of a minimal dose of gamma globulin
or even physiological saline could have been erroneously credited with
reducing the incidence of infectious hepatitis to a mere 1.7 per cent of
118 exposed adults.
Unpublished observations at Willowbrook State School' have indicated
that resistance to infection is related to the socio-economic status of
the patient. Negro children who have lived under conditions of crowding
and poor sanitation are more immune than white children of comparable
age from more highly sanitary areas.
In contrast to measles, infectious hepatitis in children occurs for the
most part as an unrecognized infection. Consequently, a history of previous
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infection is usually not available. At the present time, host susceptibility
is crudely related to the age and socio-economic status of the person.
Type of Exposure. The virus of infectious hepatitis is excreted in
the stools and is present in the blood of patients in the preclinical as well
as the acute phase of the disease. Consequently, the virus is disseminated
via the intestinal-oral circuit through human association or by the parenteral
administration of infected blood or blood products. The attack rate of
infectious hepatitis is directly proportional to the intimacy and duration
of exposure. The determination of an adequate exposure is difficult be-
cause of the lack of a laboratory tool to identify the virus in the suspected
patient or in the individual with unsuspected subclinical infection.
Antibody Content of Gamma Globulin. The IH neutralizing antibody
content of gamma globulin cannot be measured. Since gamma globulin
is prepared from large pools of adult plasma, the antibody content will
be determined by the immune status of the donor group. The high incidence
of infectious hepatitis in adults during 1959 and 1960 is a reflection of
a non-immune population. Gamma globulin prepared from adult plasma
pools collected at this time may have a low antibody content. It is con-
ceivable that a dose based on 0.01 ml./lb. of patient weight, using gamma
globulin prepared from American Red Cross Blood collected in 1940, may
provide more IH antibody than a much larger dose of 1959-60 preparation.
The variability of the IH antibody content of gamma globulin probably
parallels the variability of poliovirus antibody.
In summary, the physician who attempts to evaluate the efficacy
of gamma globulin in the prevention of infectious hepatitis is confronted
by the triple dilemma of lack of precise knowledge concerning i) the sus-
ceptibility of the host, ii) the adequacy of exposure to infective virus,
and iii) the antibody content of gammaglobulin. In view of these difficulties,
recommendations for a particular dose of gamma globulin should be based
on controlled studies in comparable age groups of similar socio-economic
status with comparable exposure and comparable lots of gamma globulin.
RECOMMENDED DOSE OF GAMMA GLOBULIN
The dose of gamma globulin currently recommended for the pre-
vention of hepatitis with jaundice ranges between 0.01 ml. and 0.06 ml.
per pound of body weight administered promptly after exposure. The
1960 edition of the American Public Health Association Control of Com-
municable Diseases in Man recommends "immune serum globulin, 0.01
ml. per pound of body weight intramuscularly. . . Enclosures in vials
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of gamma globulin distributed by the American Red Cross suggest a dosage
of 0.02 ml. per pound of body weight. The Armed Forces tri-service medical
technical bulletin on "Immunization"* recommends a dosage of 0.05 ml. per
pound for military personnel. The American Academy of Pediatrics Com-
mittee on the Control of Infectious Diseases in its 1961 report states
"the recommended dose in children is 0.04 ml./kg. body weight (approxi-
mately 0.02 ml. per pound); adults may require up to 0.1 ml./kg.' (approxi-
mately 0.05 ml. per pound)." On the basis of controlled institutional studies
completed in 1960, Krugman et al.8 suggested that the optimum dose of
gamma globulin for children and especially adults is 0.06 ml. per pound
of body weight. More recently' Gellis and McComb recommended the
smaller 0.01 ml. per pound of body weight dose for both children and
adults.
The following summary of published and unpublished controlled trials
of gamma globulin is reviewed in an attempt to clarify some of the
confusion in regard to dosage for children and adults.
STUDIES WITH LARGE DOSES OF GAMMA GLOBULIN (0.06 ml.-O.15 ml./lb.)
The first reported trial of gamma globulin by Stokes and Neefe10 in
1944 was conducted in a children's camp during an explosive water-
borne epidemic of infectious hepatitis. Gamma globulin was administered
in a dose of 0.15 ml. per pound of body weight. The attack rate was
45 per cent in the control group as compared with 5.7 per cent in the
gamma globulin group. Later in 1944, these observations were confirmed by
Havens and Paul' who studied an epidemic of infectious hepatitis in an
orphanage in New Haven. Following a dose of 0.06 ml. to 0.12 ml. gamma
globulin per pound by body weight hepatitis with jaundice was observed
in 23 per cent of the control group and 2 per cent of the inoculated group.
Both studies demonstrated about a 90 per cent reduction in incidence of
icteric hepatitis following large doses of gamma globulin administered
during acute explosive epidemics of the disease in children.
The first reported study in adults was conducted in the Armed Forces
by Gellis and associates.' The attack rate of infectious hepatitis among
683 controls was 3.7 per cent as compared with 1.0 per cent of 406
soldiers inoculated with gamma globulin 0.06 ml. per pound of body
weight. Thus, this dose of gamma globulin in adults was 73 per cent
effective in contrast to the 90 per cent effectiveness in children. The
*Army TB MED 114, Navy MED P-5052-15 and Air Force Pamphlet-5-1, dated
22 December, 1959.
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effectiveness in our Willowbrook trials with gamma globulin 0.06 ml. per
pound of body weight also exceeded 90 per cent in a controlled group of
patients, predominantly children.8
STUDIES WITH SMALL DOSES OF GAMMA GLOBULIN (0.01 ml. per lb.)
The first trial with small doses of gamma globulin (0.01 ml./lb.) was
conducted by Stokes and associates'8 in a training school for children dur-
ing an epidemic of infectious hepatitis. The attack rate in the control
group of children was 54 per cent as compared with 2 per cent in the
inoculated group. The effectiveness which exceeded 90 per cent was com-
parable to the results achieved with the larger doses. Cases of hepatitis
continued to occur in the control group for at least 8 months after the
trial began. After the first month, hepatitis with jaundice was not de-
tested in the gamma globulin group. This prolonged protective effect
was postulated by Stokes to be due to passive-active immunity.
Hsia, Lonsway and Gellis' confirmed Stokes' observations in their
well controlled study of household contacts. Alternate members of an
exposed family received gamma globulin in a dose of 0.01 ml. per pound of
body weight. The attack rate of icteric hepatitis was 27 per cent of 40
controls and 2 per cent of 57 inoculated children. Subsequently, the
studies by Drake and Ming" provided additional confirmation of the
efficacy of the small doses of gamma globulin.
In contrast with previous reports, our Willowbrook studies8"" with the
0.01 ml. per pound body weight dose of gamma globulin showed the fol-
lowing significant differences: i) an attack rate of 2 per cent in 2988
controls as compared with 0.7 per cent of 1224 inoculated inmates, that
is a 54 per cent effectiveness, and ii) no protection among 125 adult
institutional employees as compared with 456 controls; an attack rate
of 3.2 per cent in the gamma globulin group and 1.7 per cent in the
controls. In an attempt to clarify this discrepancy, the old trials of
gamma globulin were re-evaluated and new ones were begun.
RE-EVALUATION OF WILLOWBROOK TRIAL WITH GAMMA GLOBULIN 0.01 ml. lb.
The failure of the small dose of gamma globulin to protect adequately
against hepatitis in Willowbrook may have been due to at least three
factors: i) the possibility of a low hepatitis antibody content of gamma
globulin; ii) the age factor and iii) the peculiar endemic situation in the
institution.
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Antibody Content of Gamma Globulin. A single lot of gamma globulin*
was employed in the Willowbrook trial. The protective effect of this mate-
rial would be decreased if it were lacking in hepatitis antibody. Un-
fortunately, a serological test to measure infectious hepatitis antibody
is not available at this time. However, a suggestion of the presence or
absence of hepatitis antibody may be obtained by measuring the measles
and poliomyelitis neutralizing antibody content of gamma globulin.
An aliquot of the gamma globulin used for the Willowbrook trial
was tested** for the presence of neutralizing antibody. The neutralizing
antibody titers were as follows: measles - 1:200; poliomyelitis, type 1
- 1:256, type 2 - 1:512 and type 3 - 1:104. These results provided
indirect evidence that the gamma globulin employed in this study was
probably adequate and low potency was not likely to be the responsible
factor.
The Age Factor. It is well recognized that infectious hepatitis in adoles-
cents and adults is apt to be a more severe, more protracted and more
debilitating disease than in younger age groups. Inapparent and mild in-
fections are much more common in children. The dividing line in this
particular host response appears to be puberty. It seems reasonable to
postulate that the same small dose of gamma globulin which will protect
against the insignificant childhood disease may not be as effective against
the more formidable adult disease.
The above hypothesis would explain the failure of a small dose of
gamma globulin to protect the adult attendants. It would also explain the
decreased efficacy of this dose which gave only 54 per cent protection
for the inmates. An analysis of the age distribution of 4177 inmates who
participated in the study revealed that 42 per cent were over 15 years of
age.5
The Peculiar Endemic Situation in the Institution. Infectious hepatitis
has been endemic in Willowbrook for the past eight years. The attack
rate of the icteric disease has ranged between 1 and 3 per cent per annum.
Susceptible contacts have been subjected to a continuous, low-grade,
smouldering type of exposure. In contrast, in other institutional
studies"0"1 " the attack rate of hepatitis with jaundice in children has
ranged between 21 and 45 per cent. These epidemics have been explosive
and short term in type, ranging between one and eight months. In the
studies of household contacts by Brooks et al.' and by Hsia et al.' the
* Courtland Laboratories, gamma globulin lot no. 5009.
** We are indebted to Dr. Maurice Hilleman, Director, Merck Institute of Thera-
peutic Research for performing the neutralizing antibody titrations.
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attack rate in children was similar to the institutional epidemics ranging
between 27 and 35 per cent.
The decreased efficacy of the 0.01 ml. per pound dose of gamma globulin
in the Willowbrook studies may be related to the peculiar endemic situation
in the institution. Under these conditions of continuous, long term ex-
posure the small dose of gamma globulin may be sub-optimal.
EFFECT OF DOSAGE OF GAMMA GLOBULIN ON PASSIVE ACTIVE IMMUNITY
Stokes and his co-workers'3 were the first to demonstrate prolonged
protection against icteric hepatitis following administration of gamma
globulin to persons exposed in institutional outbreaks. These authors
postulated that the gamma globulin markedly attenuated the disease in
the exposed persons, thereby inducing a subclincal infection. Subsequently,
our studies8"5 tended to confirm this hypothesis.
It has been suggested that a large dose of gamma globulin will be
followed by too much passive immunity and not enough active immunity.
Preliminary studies reported by our group last year8 did not support
this hypothesis. Recently, we have had an opportunity to extend these
observations at the Willowbrook State School.*
Since May 1959, 85 patients have been studied intensively for a six
month period following admission to this institution in which infectious
hepatitis is endemic. A total of 40 patients received gamma globulin,
0.06 ml. per pound on admission; the remaining 45 patients were un-
inoculated controls.
Each patient was examined and bled at least once weekly, and more
often if necessary. The following biochemical tests of liver function were
performed: serum transaminase (SGOT), thymol turbidity, and cephalin
flocculation. Any suggestion of skin or scleral icterus was confirmed by a
serum bilirubin determination. The following criteria were established
for a diagnosis of hepatitis wzith jaundice: evidence of clinical icterus
confirmed by a serum bilirubin more than 1.0 mg. per 100 ml. and an
abnormal SGOT activity (more than 60 units). Criteria for a diagnosis of
anicteric hepatitis included a crescendo-like rise in SGOT activity plus
an abnormal elevated thymol turbidity.
The results of this study are shown in Figure 1. It is apparent that
gamma globulin in a dose of 0.06 ml. per pound did not prevent hepatitis
infection. However it did delay the occurrence of jaundice until the fifth
*We are indebted to Dr. Paul H. Hoch, New York State Commissioner of Mental
Hygiene and to Dr. Harold H. Berman, Director of Willowbrook State School for
their cooperation.
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and sixth month after admission to the institution. In the control group,
hepatitis with jaundice appeared earlier and in larger numbers.
As indicated in Figure 1 the attack rate of hepatitis with jaundice
was 7.5 per cent for the gamma globulin group as compared with 13.3 per
cent for the control group. The overall attack rate for combined icteric
and anicteric-hepatitis was almost identical for both groups, 37.5 per cent
and 37.7 per cent respectively.
The gamma globulin* employed for these studies was tested for measles
and poliomyelitis neutralizing antibody. The results of the titration were
as follows: lot 234-2: measles-1:400, poliomyelitis type 1-1:416,
type 2-1:630 and type 3-1:208 and lot 310: measles-1:200, polio-
myelitis type 1-1:630, type 2-1:630 and type 3-1:256. These data
provided indirect evidence of the presence of infectious hepatitis antibody
in the gamma globulin.
In summary, under the conditions of this study the larger dose of gamma
globulin (0.06 ml. per pound) did not prevent hepatitis infection. Conse-
quently it probably did not interfere with passive-active immunity. Admin-
istrationof the larger dose was associated with a significantly lower incidence
of hepatitis with jaundice. These observations confirmed previously reported
studies8 which indicated that the protective effect of a 0.06 ml. per pound
dose persisted for at least five months.
CONCLUSIONS
The available evidence based on published controlled studies will not
support a "blanket" recommendation for a 0.01 ml. per pound dose of
gamma globulin for all age groups and for all types of exposure to in-
fectious hepatitis. In view of the probable variability of the IH antibody
content of gamma globulin it is suggested that the current minimum
dose be 0.02 ml. per pound of body weight. The maximum dose need
not exceeed 0.06 ml. per pound.
The minimum 0.02 ml. per pound dose is recommended for children
who have had a transient, short term type of exposure; for example, a
household or school contact, an explosive institutional epidemic. The ef-
ficacy of this dose for susceptible adults is unknown.
The larger 0.06 ml. per pound dose is recommended under the following
circumstances:
*Gamma globulin prepared by E. R. Squibb & Sons, New York from plasma fur-
nished by the American Red Cross, lot numbers 234-2 and 310.
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1) for children and adults subjected to prolonged, continuous exposure
in a highly endemic area;
2) for pregnant and postmenopausal famales;
3) for patients with pre-existing hepatic disease.
A universal recommendation of 0.01 ml. per pound of body weight
may not prevent hepatitis with jaundice in a significant number of ex-
posed susceptible adults. On the other hand, administration of large doses
of gamma globulin to many adults with a high index of immunity will
waste an expensive product in limited supply. Under these circumstances
a public health officer may be justified in releasing the minimal dose.
However, it should be recognized that the most feasible dose from the
public health viewpoint is not always the most optimum dose from the
individual viewpoint.
ADDENDUM
From 1, February 1960 until 1, November 1961, one thousand new employees were
appointed at the Willowbrook State School. Of 399 adults who received 4 ml. of gamma
globulin* intramuscularly (approximatly 0.03 ml./lb. body weight) two (0.5%o) con-
tracted hepatitis with jaundice. Of 601 uninoculated adults, 27 (4.5%) acquired the
disease. Under the conditions of this study this dose of gamma globulin was 90%
effective in reducing the incidence of hepatitis with jaundice.
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